Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion

被引：28
作者：
Dagogo-Jack, Ibiayi [1 ]
Piotrowska, Zofia [1 ]
Cobb, Rosemary [1 ]
Banwait, Mandeep [1 ]
Lennerz, Jochen K. [2 ]
Hata, Aaron N. [1 ]
Digumarthy, Subba R. [1 ]
Sequist, Lecia V. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.jtho.2019.05.046
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E226 / E228
页数：4
相关论文
共 10 条
  • [1] BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
    Kulkarni, Atul
    Al-Hraishawi, Husam
    Simhadri, Srilatha
    Hirshfield, Kim M.
    Chen, Suzie
    Pine, Sharon
    Jeyamohan, Chandrika
    Sokol, Levi
    Ali, Siraj
    Teo, Man Lung
    White, Eileen
    Rodriguez-Rodriguez, Lorna
    Mehnert, Janice M.
    Ganesan, Shridar
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (18) : 5631 - 5638
  • [2] Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
    Offin, Michael
    Somwar, Romel
    Rekhtman, Natasha
    Benayed, Ryma
    Chang, Jason C.
    Plodkowski, Andrew
    Lui, Allan J. W.
    Eng, Juliana
    Rosenblum, Marc
    Li, Bob T.
    Riely, Gregory J.
    Rudin, Charles M.
    Kris, Mark G.
    Travis, William
    Drilon, Alexander
    Arcila, Maria E.
    Ladanyi, Marc
    Yu, Helena A.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 12
  • [3] Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
    Oxnard, Geoffrey R.
    Hu, Yuebi
    Mileham, Kathryn F.
    Husain, Hatim
    Costa, Daniel B.
    Tracy, Philip
    Feeney, Nora
    Sholl, Lynette M.
    Dahlberg, Suzanne E.
    Redig, Amanda J.
    Kwiatkowski, David J.
    Rabin, Michael S.
    Paweletz, Cloud P.
    Thress, Kenneth S.
    Janne, Pasi A.
    [J]. JAMA ONCOLOGY, 2018, 4 (11) : 1527 - 1534
  • [4] Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
    Piotrowska, Zofia
    Isozaki, Hideko
    Lennerz, Jochen K.
    Gainor, Justin F.
    Lennes, Inga T.
    Zhu, Viola W.
    Marcoux, Nicolas
    Banwait, Mandeep K.
    Digumarthy, Subba R.
    Su, Wenjia
    Yoda, Satoshi
    Riley, Amanda K.
    Nangia, Varuna
    Lin, Jessica J.
    Nagy, Rebecca J.
    Lanman, Richard B.
    Dias-Santagata, Dora
    Mino-Kenudson, Mari
    Iafrate, A. John
    Heist, Rebecca S.
    Shaw, Alice T.
    Evans, Erica K.
    Clifford, Corinne
    Ou, Sai-Hong, I
    Wolf, Beni
    Hata, Aaron N.
    Sequist, Lecia, V
    [J]. CANCER DISCOVERY, 2018, 8 (12) : 1529 - 1539
  • [5] Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
    Schrock, Alexa B.
    Zhu, Viola W.
    Hsieh, Wen-Son
    Madison, Russell
    Creelan, Benjamin
    Silberberg, Jeffrey
    Costin, Dan
    Bharne, Anjali
    Bonta, Ioana
    Bosemani, Thangavijayan
    Nikolinakos, Petros
    Ross, Jeffrey S.
    Miller, Vincent A.
    Ali, Siraj M.
    Klempner, Samuel J.
    Ou, Sai-Hong Ignatius
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1312 - 1323
  • [6] Sequist LV, ABSTRACT CT0033 TATT
  • [7] Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
    Soria, J. -C.
    Ohe, Y.
    Vansteenkiste, J.
    Reungwetwattana, T.
    Chewaskulyong, B.
    Lee, K. H.
    Dechaphunkul, A.
    Imamura, F.
    Nogami, N.
    Kurata, T.
    Okamoto, I.
    Zhou, C.
    Cho, B. C.
    Cheng, Y.
    Cho, E. K.
    Voon, P. J.
    Planchard, D.
    Su, W. -C.
    Gray, J. E.
    Lee, S. -M.
    Hodge, R.
    Marotti, M.
    Rukazenkov, Y.
    Ramalingam, S. S.
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02) : 113 - 125
  • [8] Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers
    Vojnic, Morana
    Kubota, Daisuke
    Kurzatkowski, Christopher
    Offin, Michael
    Suzawa, Ken
    Benayed, Ryma
    Schoenfeld, Adam J.
    Plodkowski, Andrew J.
    Poirier, John T.
    Rudin, Charles M.
    Kris, Mark G.
    Rosen, Neal X.
    Yu, Helena A.
    Riely, Gregory J.
    Arcila, Maria E.
    Somwar, Romel
    Ladanyi, Marc
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (05) : 802 - 815
  • [9] RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
    Yao, Zhan
    Gao, Yijun
    Su, Wenjing
    Yaeger, Rona
    Tao, Jessica
    Na, Na
    Zhang, Ying
    Zhang, Chao
    Rymar, Andrey
    Tao, Anthony
    Timaul, Neilawattie M.
    Mcgriskin, Rory
    Outmezguine, Nathaniel A.
    Zhao, HuiYong
    Chang, Qing
    Qeriqi, Besnik
    Barbacid, Mariano
    de Stanchina, Elisa
    Hyman, David M.
    Bollag, Gideon
    Rosen, Neal
    [J]. NATURE MEDICINE, 2019, 25 (02) : 284 - +
  • [10] Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
    Yao, Zhan
    Yaeger, Rona
    Rodrik-Outmezguine, Vanessa S.
    Tao, Anthony
    Torres, Neilawattie M.
    Chang, Matthew T.
    Drosten, Matthias
    Zhao, Huiyong
    Cecchi, Fabiola
    Hembrough, Todd
    Michels, Judith
    Baumert, Herve
    Miles, Linde
    Campbell, Naomi M.
    de Stanchina, Elisa
    Solit, David B.
    Barbacid, Mariano
    Taylor, Barry S.
    Rosen, Neal
    [J]. NATURE, 2017, 548 (7666) : 234 - +
1